Expose MASH [Formerly NASH]

Exploring FIB-4 for Fibrosis Risk Assessment


Listen Later

On this episode, join experts Mazen Noureddin, MD, MHS (Transplant Hepatologist and Professor of Medicine at Houston Methodist Hospital), Jay Shubrook, DO, FACOFP, FAAFP (Diabetologist and Professor of Medicine at Touro University California) and Mohammad Siddiqui, MD (Gastroenterologist/Hepatologist and Associate Professor at Virginia Commonwealth University), in a discussion that highlights the significance of noninvasive tests in screening patients who are at risk for MASH. These experts enlighten us on how to incorporate the FIB-4 index in clinical practices for fibrosis risk assessment and how the scores generated are used to provide recommendations for further management approaches. The conversation further explores the strengths and limitations of using this test. Join us as we discuss the importance of screening for fibrosis using FIB-4.

This program is intended for clinicians in the US only. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk Inc. This podcast is not to be used as medical advice and is intended for educational purposes only.

Faculty Presenters:

Mazen Noureddin, MD, MHS
Transplant Hepatologist and Professor of Medicine
Houston Methodist Hospital
Houston, TX

Jay Shubrook, DO, FACOFP, FAAFP
Diabetologist and Professor of Medicine
Touro University
Vallejo, California

Mohammad Siddiqui, MD
Gastroenterologist/Hepatologist and Associate Professor
Virginia Commonwealth University
Richmond, Virginia


Click here for full reference list

References

American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S52-S76.

Cusi K, Budd J, Johnson E, Shubrook J. Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know. Diabetes Spectr. 2024;37(1):29-38.

Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocr Pract. 2022;28(5):528-562. 

De Lorenzo S, Tovoli F, Mazzotta A, et al. Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role. Cancers (Basel). 2020;12(11):3182.

Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554.

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.

Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669.

Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931-939.

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.

Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371-378.

Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165(4):1080-1088.

...more
View all episodesView all episodes
Download on the App Store

Expose MASH [Formerly NASH]By Novo Nordisk

  • 4.2
  • 4.2
  • 4.2
  • 4.2
  • 4.2

4.2

10 ratings


More shows like Expose MASH [Formerly NASH]

View all
Docs Who Lift by Docs Who Lift

Docs Who Lift

388 Listeners

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

10 Listeners